Kapat
Popüler Videolar
Moods
Türler
English
Türkçe
Popüler Videolar
Moods
Türler
Turkish
English
Türkçe
A new method for developing a consensus guideline in AML
6:33
|
Loading...
Download
Lütfen bekleyiniz...
Type
Size
İlgili Videolar
A new method for developing a consensus guideline in AML
6:33
|
Measurable Residual Disease in Acute Myeloid Leukemia MRD in AML
34:52
|
Why could IMGN632 be an important treatment option for AML?
2:25
|
AIH Treatment Guidelines: How Are They Created, and Why Do We Need Them?
30:27
|
Hematological Disorders using Targeted Panel Sequencing | Illumina Webinar
56:29
|
Minimal Residual Disease (MRD) Overview | LRF Ed Forum Series
56:04
|
How can venetoclax combinations improve outcome for FLT3-mutant AML?
6:46
|
UROwebinar: Renal, bladder and prostate cancer guidelines 2021: From guidelines to real world
1:05:21
|
Antimicrobial prophylaxis and therapy in Acute Leukemia (by Jayastu Senapati)
1:07:47
|
Prof. David Barnett - To QC or Not to QC - A Reflection on a Career in EQA
57:01
|
Innovative solutions for diagnosis and minimal residual disease assessment in acute
1:56:11
|
Detection and Interpretation of Complex Myeloid Leukemia Mutations
47:31
|
Comparing the ICC and WHO classifications for secondary AML and their impact on clinical practice
3:20
|
Considerations for Developing the Indications and Usage Section of Labeling (3/9) Labeling 2017
59:59
|
Applications of Next-Gen Sequencing
48:43
|
Supportive Care for Chronic GVHD
1:05:36
|
Secondary Cancers 2021
52:38
|
Biology and Therapy of Eosinophilic MPNs
27:38
|
Next-Generation Sequencing
1:00:56
|
GBCI: A Catalyst for Change in Global Oncology & Noncommunicable Diseases
1:00:28
|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa
